BIIB

#462
Biogen Inc. - Common Stock
195.9 1 USD
-0.79%
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
195.55
198.00
Yıllık Aralık
121.06
205.97
Günlük Değişim
-0.79%
Aylık Değişim
+0.96%
6 Aylık Değişim
+8.75%
Yıllık Değişim
+48.63%
Önceki Kapanış
197.4 7
Open
195.5 5
Düşük
195.5 5
High
198.0 0
Hacim
73
Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler
Çeyreklik Yıllık
  • Market Capitalization 28.92 B
  • Employee 7 500
  • Founded 1978
  • CEO Chris Viehbacher
  • Website www.biogen.com
  • Headquarter Delaware, United States
  • FIGI BBG000C17X76
  • Industry İlaç Üreticileri - Genel
Toplam gelir
Net kar
Temel hisse başına kazanç (Temel EPS)
Toplam borç
Serbest nakit akışı
Nakit ve eşdeğerleri
Fiyat/kazanç oranı
20.02
Fiyat/satışlar oranı
2.62

Biogen Inc. - Common Stock

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

Haberler